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Background: The incidence of melanoma is rising. Early detection is associated with a more favourable outcome.
The factors that influence the timing of a patient’s presentation for medical assessment are not fully understood.
The aims of the study were to measure the nature and duration of melanoma symptoms in a group of patients
diagnosed with melanoma within the preceding 18 months and to identify the symptoms and barriers associated
with a delay in presentation.
Methods: A questionnaire was distributed to a random sample of 200 of the 963 melanoma patients who had
participated in the Cancer Patient Experience Survey 2010 and were known to be alive 1 year later. Data were
collected on symptoms, duration of symptoms prior to presentation and the reasons for not attending a doctor
sooner.
Results: A total of 159 patients responded to the questionnaire; 74 (47%) were men; mean age was 62 (range 24–
90) years. Of the 149 patients who reported a symptom, 40 (27%) had a delayed presentation (i.e. >3 months). A
mole growing bigger was the most common symptom and reporting this symptom was significantly associated
with a delayed presentation (odds ratio (OR) 2.04, 95% confidence interval (95% CI) 1.14–5.08). Patients aged
≥65 years were less likely to report a barrier to presentation and were less likely to delay than those under 40,
although this was of borderline statistical significance (OR 0.28, 95% CI 0.08–1.00).
Conclusions: This study highlights that an enlarging mole is a significant symptom influencing the timing of
presentation. Increasing public awareness of the signs of melanoma and of the importance of early presentation is
desirable. Health professionals should take advantage of the opportunity to educate patients on such symptoms
and signs where feasible. Further exploration of the barriers to presentation in younger people should be
considered.
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The incidence of melanoma is rising, with a greater than
four-fold increase within the past 40 years in the United
Kingdom (UK) [1]. In 2012, there were 2148 deaths from
melanoma in the UK [1]. Thin, non-ulcerated melano-
mas (Breslow thickness <1 mm) have the best prognosis* Correspondence: S.J.O'Shea@leeds.ac.uk
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contribute to better outcomes. Urgent referral to special-
ist care is indicated in cases of suspected melanoma and
the 2-week wait system is designed to limit healthcare-
associated delay. Patient factors, however, crucially influ-
ence the timing of presentation [3–11]. It has previously
been shown that changing moles may not cause patient
concern or even be recognised as a feature of skin can-
cer [12] and the reasons for delay are complex, including
a lack of recognition of the symptoms as significant and
not wanting to “waste” the doctor’s time [8, 10, 11, 13].le is distributed under the terms of the Creative Commons Attribution 4.0
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delay in order to effect change and to overcome obsta-
cles to early detection. In this study, we report the na-
ture of symptoms prompting presentation to medical
services, reported by melanoma patients participating in
a UK survey of cancer patients.
Methods
In November 2011, we sent a questionnaire (NHS Can-
cer Symptoms Questionnaire (Additional file 1)) to a
random sample of 200 patients with melanoma (Inter-
national Classification of Diseases-10 (ICD-10) code
C43) [14]. These were drawn from a sample of 963 pa-
tients with melanoma who had responded to the English
Department of Health’s Cancer Patient Experience Sur-
vey in mid-2010 [15], were still alive in November 2011,
and had agreed that they could be recontacted.
Of these 200, one further person was subsequently re-
ported to have died. The questionnaire asked about the
nature and duration of melanoma-related symptoms
prior to patient presentation at their general practitioner.
Participants could tick one or more boxes in response to
each question within the questionnaire, i.e. lists were
provided, consisting of the most common symptoms
(e.g. a mole changing shape or growing bigger), pre-
defined time intervals (e.g. <2 weeks, more than 2 weeks
but less than 4 weeks) and possible reasons for delay
(e.g. I didn’t realise the problem or symptom was ser-
ious). Free text boxes were also included to capture any
additional information that was not included in the list.
Further details of the methods are available in a previous
report [4].
As a survey of perceptions of National Health Service
(NHS) patient care, no formal ethical approval was
sought for the Cancer Patient Experience Survey by the
Department of Health. However, all patients approached
as part of the survey had given written consent to being
recontacted.
All participants were assigned an Index of Multiple
Deprivation (IMD), based on the average level of
deprivation of the area where they lived. Participants
were then categorised into five categories according to
quintiles of IMD for all of England [16].
The duration of symptoms was calculated as the time
interval between first noticing the symptom that led to
diagnosis and presenting to a doctor. A delay in presenta-
tion was defined as a duration of symptoms of 3 months
or more.
In order to estimate the risk of a delay in presentation,
we calculated odds ratios (with 95% confidence inter-
vals) for delay according to age (<40, 40–64, ≥65 years),
gender, deprivation index category, tumour site and bar-
riers to presentation reported. We also calculated odds
ratios for delay by symptoms reported; in each analysisthe reference group was the group of patients who did
not report that particular symptom. It was not possible
to calculate adjusted estimates due to small numbers.
We also examined whether age, gender and deprivation
index category were associated with reporting barriers,
using χ2 tests.
All statistical analyses were done using STATA v12.
Results
There was an 80% response rate (n = 159) to the request
for completion of the second survey. Age at diagnosis was
available for 145 patients. The mean age was 62 (range
24–90) years, which is slightly older than UK norms for
melanoma patients. Forty-three per cent (n = 68) of pa-
tients were aged 65 years or older. Forty-seven per cent
of participants (n = 74) were male, with a male-female
ratio of 1:1.1, which is similar to the overall male:female
ratio for melanoma in the UK [1]. Twenty-seven per
cent (n = 43) and 7% (n = 11) of respondents were in
the least and most deprived deprivation index categor-
ies, respectively. The ratio of those in the least deprived
to most deprived categories was 3.9:1 (compared to
2.7:1 between 2006 and 2010 in England overall) [17].
Ethnicity was available for 140 patients. All described
their ethnicity as White, which reflects the epidemi-
ology of melanoma, occurring more frequently in
people with paler skin types [18]. Fifteen per cent (n =
24) of patients had melanomas of the head and neck,
30% (n = 48) on the trunk, 24% (n = 38) on the upper
limb and 28% (n = 44) on the lower limb. Site was not
recorded in 5 cases.
Of the 159 respondents, 149 (94%) reported symptoms
at the time that medical help was sought (Table 1). Ten
patients did not list any symptoms, 3 of whom reported
the incidental detection of ‘moles’ by health professionals
during consultations for other conditions. Participants
could list one or more symptoms. Of those patients
reporting symptoms, 89 (60%) patients reported either a
mole growing bigger, changing shape or changing colour.
The most commonly reported symptom (39%) was a ‘mole
growing bigger’. Of the 149 patients who reported symp-
toms, 76% (n = 113) described a change in a pre-existing
mole rather than a new mole or lesion.
The duration of symptoms was reported by 141 pa-
tients (Table 1). Of the 149 patients who reported symp-
toms, 26% (n = 39) reported a mole bleeding or crusting
and of these only 18% (n = 7) had a presentation of more
than 3 months (defined as a delayed presentation). Only
2% (n = 3) of patients presented with a lump in the neck,
groin or armpit, all of whom presented within 4 weeks.
A delay of greater than 3 months was reported by 27%
of patients (n = 40). Table 2 shows the factors that were
associated with a delay in presentation. Patients aged 65
and over were less likely to delay, compared to patients
Table 2 Factors associated with a delay in symptomatic presentation of more than 3 months (among 141 patients reporting any
symptoms and with data on time to presentation available)
N (%) delaying
presentation
Odds ratio for delay 95% CI p
Age (years) <40 6/12 (50.0) 1.00
40–64 19/57 (33.3) 0.50 0.14–1.76 0.28
≥65 13/60 (21.7) 0.28 0.08–1.00 0.05
Sex Male 16/66 (24.2) 1.00
Female 24/75 (32.0) 1.32 0.77–2.26 0.32
Site of primary melanoma Head and neck 8/22 (36.4) 1.00
Trunk 9/43 (20.9) 0.46 0.15–1.45 0.19
Limbs 21/71 (29.6) 0.74 0.27–2.01 0.55
Unspecified 2/5 (40.0) 1.17 0.16–8.53 0.88
New lump on skin or new mole No 31/119 (26.1) 1.00
Yes 9/22 (40.9) 1.97 0.77–5.05 0.16
Mole changing shape or colour
or growing bigger
No 11/57 (19.3) 1.00
Yes 29/84 (34.5) 2.20 0.99–4.89 0.05
Mole growing bigger No 18/85 (21.2) 1.00
Yes 22/56 (39.3) 2.04 1.14–5.08 0.02
Mole changing colour No 22/94 (23.4) 1.00
Yes 18/47 (38.3) 2.03 0.95–4.33 0.07
Mole changing shape No 24/99 (24.2) 1.00
Yes 16/42 (38.1) 1.92 0.89–4.17 0.10
Mole itchy No 29/112 (25.9) 1.00
Yes 11/29 (37.9) 1.75 0.74–4.14 0.20
Mole bleeding or crusting No 33/103 (32.0) 1.00
Yes 7/38 (18.4) 0.47 0.19–1.20 0.12
The odds ratio for delay was not calculated for a lump in the neck, groin or armpit as no patients reporting this symptom had a delayed presentation. For the
odds ratios by symptom, the reference group is the group of patients who did not report that particular symptom. Age at diagnosis was available for 129 of the
141 patients reported in this table
Table 1 Type of symptoms and the time interval from onset of symptoms to presentation among melanoma patients reporting
symptoms
Symptom ≤4 weeks 4 weeks – 3 months >3 months Duration missing Number reporting symptom
(% of all patients)
n (%) n (%) n (%) n (%) n (%)
New lump on skin or new mole a 8 (34.8) 5 (21.7) 9 (39.1) 1 (4.3) 23 (15.4)
Mole changing shape, colour or
growing bigger b
41 (46.1) 14 (15.7) 29 (32.6) 5 (5.6) 89 (59.7)
Mole growing bigger 24 (43.1) 9 (15.5) 22 (37.9) 2 (3.5) 58 (38.9)
Mole changing colour 22 (44.9) 7 (14.3) 18 (36.7) 2 (4.1) 49 (32.9)
Mole changing shape 19 (43.2) 7 (15.9) 16 (36.4) 2 (4.6) 44 (29.5)
Mole itchy 10 (31.3) 8 (25.0) 11 (34.4) 3 (9.4) 32 (21.5)
Mole bleeding or crusting 21 (53.9) 10 (25.6) 7 (18.0) 1 (2.6) 39 (26.2)
Lump in neck, groin or armpit 3 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (2.0)
Of the 159 participants, data for symptoms were available for 149 patients and data for duration of symptoms were available for 141 patients. Participants could
list more than one symptom
aThe symptom list on the questionnaire did not include ‘new mole’. Participants who ticked ‘other’ and wrote free text suggesting a new mole have been recoded
within the category ‘new lump on skin’
bThe duration of these symptoms were reported separately and together, as melanomas, particularly of the superficial spreading subtype, might display a
combination of these features
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borderline statistical significance. Gender and tumour
site were not significantly related to delay, although we
noted that the proportion delaying more than 3 months
was highest in patients with lesions on the head and
neck compared to other sites (36% versus 27%; data not
shown). Deprivation index category was not significantly
associated with delay (data not shown). Those patients
who reported ‘a mole growing bigger’ were more likely
to have a delayed presentation compared to those who
didn’t report a mole growing bigger (OR 2.04, 95% CI
1.14–5.08). Those who reported a mole changing colour
or a mole changing shape were also more likely to have
a delayed presentation than those who did not report
these symptoms, but these associations did not reach
statistical significance.
Of the 149 patients reporting symptoms, 55% (n = 82)
reported a barrier to symptomatic presentation, and this
was associated with a greater delay in presentation (OR
5.87, 95% CI 2.37–14.50; data not shown). Forty-four
per cent (n = 66) had not realised that the symptom was
serious, which was the most common barrier reported
(Table 3). Other types of barrier were much less com-
monly reported. People aged 65 and over were less likely
to report barriers to presentation than younger people
(48% versus 68%, p = 0.02) but there were no significant
differences by gender or deprivation index category (data
not shown).
Discussion
This was a mailed questionnaire study with a good re-
sponse rate of 80%. Although the responders were older
than the average melanoma patient within the UK popula-
tion, the sample was an appropriate reflection of the sexTable 3 Reported barriers to symptomatic presentation among
149 melanoma patients who reported at least one symptom
Barrier reported n (%)
I didn’t realise the symptom was serious 66
(44.3)
I was worried about wasting the doctor’s time 13 (8.7)
I had too many other things to worry about at the time 9 (6.0)
I was too busy to make time to go to the doctor 6 (4.0)
I was too worried about what the doctor might find 5 (3.4)
I was too scared to go and see the doctor 5 (3.4)
It was difficult to make an appointment with the doctor 7 (4.7)
I was too embarrassed to go to see the doctor 1 (0.7)
I found my doctor difficult to talk to 1 (0.7)
I didn’t feel confident talking about my symptoms with the
doctor
1 (0.7)
It was difficult to arrange transport to the doctor’s 0 (0.0)
Of the 149 patients reporting symptoms, 82 reported a barrier to symptomatic
presentation. Patients could select more than one barrierdistribution of melanoma [1]. The participants were more
affluent than the UK population in general, which has
been noted previously [17]. This questionnaire was part of
a larger study, aiming to capture data across a broad
spectrum of cancer types. The sample size, while small,
was selected to assess feasibility, and to facilitate estima-
tion of symptom prevalence in the entire group of patients
with all cancers.
The most commonly reported presenting symptom
was ‘a mole growing bigger’ and this was the only symp-
tom significantly associated with delay. Although growth
of a melanocytic lesion is characteristic of melanoma ac-
knowledged by the ABCDE rule [19] (where E indicates
“evolution”), it is normal for moles or melanocytic nevi
to change through early life. Moles appear in childhood,
grow in early adult life and then stop growing, usually at
under 5 mm in diameter. It is, perhaps, understandable
that patients may seek advice only when they notice an-
other change in the lesion, such as irregularity of shape,
or even a combination of changes. We would suggest
that there is a need for health promoters to develop the
public’s knowledge and skills in order to distinguish the
natural history of moles (melanocytic naevi) from that of
a melanoma, albeit a challenging task. This study high-
lights the importance of education about the diameter
(“D” ≥6 mm) and evolution (“E”) of lesions, in particular.
Growth of moles over the age of 40 is much less com-
mon than in younger people, but thereafter it is normal
to develop a variety of other harmless skin lesions, such
as seborrhoeic keratoses and cherry angiomas. There-
fore, such patients become accustomed to developing
new lesions. The challenge for health promoters is to
teach them how to distinguish benign from malignant.
The proportion of patients who presented late, having
reported moles changing colour and shape was similar
to those delaying before reporting a mole getting bigger,
at around 35 to 40%. We hypothesise that the diagnostic
difficulties experienced in this regard are similar as for
growth in size.
The participants in this study appeared to recognise
bleeding or a lump as being more serious. A greater pro-
portion of patients with this symptom presented within
3 months although the odds ratio for delay was not sta-
tistically significant. Bleeding is known to occur more
frequently in thicker tumours [20] and appears to be a
more recognisable symptom by patients [11]. In other
cancers, bleeding is perceived as an alarm symptom and
is associated with a more prompt presentation when the
source is urinary but not rectal [4].
Twenty-seven per cent of melanoma patients in this
study did not seek medical attention for at least 3 months
after a symptom was first noted. This suggests that a
substantial number of patients within this group had a
delayed presentation. This is concerning, given that the
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readily visualised. Therefore, if a changing lesion is lo-
cated at a visible body site, it would be amenable to early
detection, provided the significance of the symptom(s) is
appreciated. In the UK, it is NHS policy that a patient
referred urgently to specialist care due to suspicion of
cancer, would be seen within 2 weeks of referral [21].
We had hypothesised that tumour site and gender
might have influenced delay. Older men are a ‘high-risk’
group for melanomas with a poorer prognosis: they tend
to present with thicker tumours, at sites that are more
difficult for patients to see, such as the back [20]. Mela-
nomas affecting the head and neck tend to be thicker
and have previously been shown to be associated with
delay [22] but this was not replicated in our study. Fur-
ther research with a larger sample size would be needed
to analyse for interactions between age and gender on
the delay in presentation by symptoms. Since awareness
of the need to have the symptom evaluated may be influ-
enced by the level of education and previous attendance
at a dermatology clinic, additional research is needed to
evaluate these influences.
More than half of the respondents (55%) reported fac-
tors that might put them off going to a doctor and this
increased the time interval to presentation. Some pa-
tients have perceived themselves to be “low-risk” [11]
and have reported a lack of general malaise, which might
have contributed to delay [12]. Patients have also noted
that they worry about attending their general practi-
tioner (GP) for fear of creating a “fuss” [13]. Interest-
ingly, those patients aged 65 years and over were less
likely to report barriers than their younger counterparts.
The survey was completed by participants within ap-
proximately 18 months of a diagnosis of melanoma. This
interval may have contributed to recall bias and impreci-
sion in the recall [23]. Some selection bias might also
have been introduced, as study participants were se-
lected from those patients who were known to be alive
1 year after the Cancer Patient Experience Survey.
Further, the respondents might have been more likely
to have a better disease course [6]. Clinical stage was not
recorded and therefore, it was not possible to assess its
impact on the results. In an effort to minimize selection
bias, a random sample was chosen, however, those with
less aggressive tumours may have been more likely to
participate.
A further limitation of the study was that, by virtue of
the study design, a number of clinical and histological fea-
tures which could have influenced outcome were not re-
corded, e.g. histological subtype. Nodular melanoma tends
to follow a more aggressive clinical course than the super-
ficial spreading subtype [24], lacking a precancerous or “in
situ” phase, whilst desmoplastic melanomas generally
carry a better prognosis, tending to present with localizeddisease [25, 26]. The biology of all melanomas may not be
the same: nodular melanomas are also believed to pro-
gress rapidly [27]. This means that a similar interval be-
tween symptom onset and presentation could result in
differences in tumour thickness related to the biological
behaviour of the tumour [27]. It was not possible to deter-
mine whether or not delay was influenced by melanoma-
specific features, e.g. the lesion lacking pigmentation
(amelanotic) or due to differences in Breslow depth or ul-
ceration. ICD-10 coding was used as an indicator for body
site but this method of grouping included a combination
of different histological subtypes within the same code.
Patients with early melanoma tend to feel well and, as a
result, may not heed the initial symptoms [12].
This study suggests that barriers might influence the
timing of presentation in melanoma patients. Such bar-
riers to presentation should be explored further. Psycho-
social factors have previously been reported to have
more influence on younger patients with melanoma
[28]. Work and childcare commitments might be con-
tributing factors, although this was not specifically ex-
plored in our study. Older patients may have reported
fewer barriers because they were already attending their
doctor with other health problems but future studies
may clarify the reasons for this association.
Conclusions
The commonest symptoms of cutaneous melanoma are
changes in size, shape or colour. This study suggests that
patients commonly take some time to identify these
changes as being of concern. We hypothesise that this
may result from difficulties in identifying such changes,
when normal moles do change with time and a number
of benign skin lesions commonly develop on the ageing
skin. We would argue that promoting public awareness
about the dangers of changing skin lesions is desirable.
Barriers to presentation were frequently cited by partici-
pants in this study. It is crucial to achieve a better un-
derstanding of these barriers in order to optimise the
timing of presentation among melanoma patients, where
early detection is paramount.
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Additional file 1: NHS Cancer Symptoms Questionnaire. This
questionnaire was completed by study participants. Details of symptoms,
symptom duration and barriers to presentation were recorded. (PDF 276 kb)
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